Publications
2024
Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity.
Kennedy, P. T., Saulters, E. L., Duckworth, A. D., Lim, Y. J., Woolley, J. F., Slupsky, J. R., . . . Dahal, L. N. (2024). Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity.. Molecular therapy : the journal of the American Society of Gene Therapy, 32(2), 457-468. doi:10.1016/j.ymthe.2023.11.028
Differential Regulation of the Stimulator of Interferon Genes pathway in Human Papillomavirus positive and negative Head and Neck Cancers.
Saulters, E., Kennedy, P. T., Carter, R. J., Alsufyani, A., Jones, T. M., Woolley, J. F., & Dahal, L. N. (2024). Differential Regulation of the Stimulator of Interferon Genes pathway in Human Papillomavirus positive and negative Head and Neck Cancers.. Cancer research communications. doi:10.1158/2767-9764.crc-23-0299
2023
Neuroblastoma: an ongoing cold front for cancer immunotherapy.
Kennedy, P. T., Zannoupa, D., Son, M. H., Dahal, L. N., & Woolley, J. F. (2023). Neuroblastoma: an ongoing cold front for cancer immunotherapy.. Journal for immunotherapy of cancer, 11(11), e007798. doi:10.1136/jitc-2023-007798
Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunity
Data from STINGing Viral Tumors: What We Know from Head and Neck Cancers
Saulters, E., Woolley, J. F., Varadarajan, S., Jones, T. M., & Dahal, L. N. (2023). Data from STINGing Viral Tumors: What We Know from Head and Neck Cancers. doi:10.1158/0008-5472.c.6513438
Synthetic STING agonists elicit powerful vaccine adjuvancy providing robust central memory and anti-tumour effects
2022
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms
Simpson, A. P., Roghanian, A., Oldham, R. J., Chan, H. T. C., Penfold, C. A., Kim, H. J., . . . Cragg, M. S. (2022). FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. CELL REPORTS, 40(3). doi:10.1016/j.celrep.2022.111099